Trium Capital LLP Astrazeneca PLC Transaction History
Trium Capital LLP
- $801 Million
- Q1 2025
A detailed history of Trium Capital LLP transactions in Astrazeneca PLC stock. As of the latest transaction made, Trium Capital LLP holds 102,641 shares of AZN stock, worth $7.37 Million. This represents 0.94% of its overall portfolio holdings.
Number of Shares
102,641Holding current value
$7.37 Million% of portfolio
0.94%Shares
1 transactions
Others Institutions Holding AZN
# of Institutions
1,385Shares Held
478MCall Options Held
6.08MPut Options Held
4.44M-
Price T Rowe Associates Inc Baltimore, MD60.4MShares$4.33 Billion0.46% of portfolio
-
Primecap Management CO Pasadena, CA41MShares$2.94 Billion2.12% of portfolio
-
Capital International Investors Los Angeles, CA37.5MShares$2.69 Billion0.48% of portfolio
-
Bank Of America Corp Charlotte, NC24MShares$1.72 Billion0.13% of portfolio
-
Franklin Resources Inc San Mateo, CA19.5MShares$1.4 Billion0.37% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $222B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...